In line with the paradoxical activation of the MAPK pathway by type I BRAF inhibitors [28], we found that the addition of encorafenib enhanced the effects of sotorasib withdrawal and converted withdrawal-resistant cancer cells to withdrawal-sensitive cancer cells. This evidence concerns the gene BRAF and cancer.